← All organizations

Swedish Orphan

For profitContributed to NME

Also known as: SWEDISH ORPHAN

Phase 1 Phase 2 Phase 3 Phase 4

First marketed drug

First NDA

Last known activity

Jan 18, 2002

Acquired by Swedish Orphan Biovitrum → Advent International on Jan 1, 2010

Timeline

1980s

Jan 1, 1988
Swedish Orphan— Founded

1990s

Jun 19, 1998
palivizumab— Marketing Organization

2000s

Jan 18, 2002
nitisinone— NDA Organization

2010s

Jan 1, 2010
Swedish Orphan Biovitrum— Acquired By

2020s

Sep 8, 2021
Advent International— Now

Indications

Approved for

Tyrosinemias

Marketed drugs (2)

Details

Founded: Stockholm, SE Jan 1, 1988
First NDA: Jan 18, 2002
Last known activity: Jan 18, 2002

Designations held

Orphan drug
Fast track
Priority review